腾博会官网·[中国]-诚信为本,专业服务!

REDEMPTION OF THE BONDS

VOLUNTARY ANNOUNCEMENT - APPLICATION FOR MARKETING OF CATEGORY I INNOVATIVE DRUG TQB2450 INJECTION IN COMBINATION WITH ANLOTINIB HYDROCHLORIDE CAPSULES FOR THE INDICATION OF FIRST-LINE TREATMENT OF SMALL CELL LUNG CANCER ACCEPTE

VOLUNTARY ANNOUNCEMENT - ENTERED INTO EXCLUSIVE COMMERCIAL COOPERATION AGREEMENT WITH BOAN BIOTECH

MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 31 DECEMBER 2022

VOLUNTARY ANNOUNCEMENT - ENTERED INTO EXCLUSIVE COMMERCIAL COOPERATION AGREEMENT

VOLUNTARY ANNOUNCEMENT - ENTERED INTO EXCLUSIVE PROMOTION AGREEMENT

VOLUNTARY ANNOUNCEMENT - COMPLETION OF PATIENT ENROLLMENT IN PHASE III CLINICAL TRIAL OF RECOMBINANT HUMAN COAGULATION FACTOR VIIA FOR INJECTION

VOLUNTARY ANNOUNCEMENT - IND APPLICATION OF INNOVATIVE MEDICINE “TCC1727” FILED WITH AND ACCEPTED BY FDA